Our analysis demonstrates the outcomes of classifying older AML patients based on a precision-based medicine assignment of the LLS Beat AML Master Study using both targetable cytogenetic abnormalities and gene mutations found in dominant mutational clones, defined as those having VAF ≥ 0.3, or VAF ≥ 0.2 (in cases with no selected mutations with VAF ≥ 0.3), or FLT3-ITD allelic ratio of ≥ 0.05. This evidence concerns the gene FLT3 and acute myeloid leukemia.